Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
Am J Hematol
    May 2024
  1. MOU E, Fernandez-Pol S, Li S, Rieger KE, et al
    Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.
    Am J Hematol. 2024;99:985-988.
    >> Share

    April 2024
  2. CHOQUET S, Soussain C, Azar N, Morel V, et al
    CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
    Am J Hematol. 2024 Apr 8. doi: 10.1002/ajh.27316.
    >> Share

    March 2024
  3. STUVER R, Mian A, Brown S, Devlin S, et al
    BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Am J Hematol. 2024 Mar 25. doi: 10.1002/ajh.27291.
    >> Share

  4. LUNNING MA, Wang HL, Hu ZH, Locke FL, et al
    Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
    Am J Hematol. 2024 Mar 19. doi: 10.1002/ajh.27283.
    >> Share

  5. ONG SY, Zain JM
    Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.
    Am J Hematol. 2024;99:439-456.
    >> Share

    February 2024
  6. KITTAI AS, Hang Y, Bhat SA, Clark A, et al
    Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
    Am J Hematol. 2024 Feb 15. doi: 10.1002/ajh.27241.
    >> Share

  7. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
    Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
    >> Share

  8. WILSON MR, Kirkwood AA, Wong Doo N, Soussain C, et al
    Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
    Am J Hematol. 2024;99:E46-E50.
    >> Share

    January 2024

  9. Correction to "Analysis of 60 Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Treated with CD7-targeted Chimeric Antigen Receptor-T Cell Therapy".
    Am J Hematol. 2024 Jan 15. doi: 10.1002/ajh.27217.
    >> Share

  10. CERHAN JR, Maurer MJ, Link BK, Feldman AL, et al
    The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
    Am J Hematol. 2024 Jan 13. doi: 10.1002/ajh.27202.
    >> Share

  11. QIAN H, Yang X, Zhang T, Zou P, et al
    Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.
    Am J Hematol. 2024 Jan 10. doi: 10.1002/ajh.27198.
    >> Share

    November 2023
  12. AL-SARAYFI D, Brink M, Chamuleau MED, Brouwer R, et al
    R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study.
    Am J Hematol. 2023 Nov 28. doi: 10.1002/ajh.27151.
    >> Share

  13. HONG HG, Gouveia MH, Ogwang MD, Kerchan P, et al
    Sickle cell allele HBB-rs334(T) is associated with decreased risk of childhood Burkitt lymphoma in East Africa.
    Am J Hematol. 2023 Nov 27. doi: 10.1002/ajh.27149.
    >> Share

  14. SAIFI O, Lester SC, Breen WG, Rule WG, et al
    Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
    Am J Hematol. 2023 Nov 11. doi: 10.1002/ajh.27155.
    >> Share

  15. REJESKI K, Wang Y, Albanyan O, Munoz J, et al
    The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
    Am J Hematol. 2023;98:1699-1710.
    >> Share

    October 2023

  16. Abstracts from the 2023 Lymphoma, Leukemia and Myeloma Congress October 18-21, 2023.
    Am J Hematol. 2023;98 Suppl 5:S3-S57.
    >> Share

    September 2023
  17. ZHANG X, Yang J, Li J, Qiu L, et al
    Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
    Am J Hematol. 2023 Sep 23. doi: 10.1002/ajh.27094.
    >> Share


  18. Erratum to: Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Am J Hematol. 2023 Sep 21. doi: 10.1002/ajh.27103.
    >> Share

  19. ONG SY, Pak S, Mei M, Wang Y, et al
    Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
    Am J Hematol. 2023 Sep 5. doi: 10.1002/ajh.27069.
    >> Share

    August 2023
  20. TAVAKKOLI M, Barta SK
    2024 Update: Advances in the risk stratification and management of large B-cell lymphoma.
    Am J Hematol. 2023 Aug 30. doi: 10.1002/ajh.27075.
    >> Share

  21. DENG L, Li Z, Zhang H, Huang H, et al
    Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
    Am J Hematol. 2023 Aug 30. doi: 10.1002/ajh.27064.
    >> Share

  22. HU H, Shklovskaya E, Deva A, Xu H, et al
    Diagnosis of breast implant associated anaplastic large cell lymphoma by analysis of cytokines in peri-implant seromas.
    Am J Hematol. 2023 Aug 30. doi: 10.1002/ajh.27055.
    >> Share

  23. KAROLOVA J, Kazantsev D, Svaton M, Tuskova L, et al
    Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.
    Am J Hematol. 2023 Aug 21. doi: 10.1002/ajh.27044.
    >> Share

  24. CHEAH CY, Seymour JF
    Marginal zone lymphoma: 2023 update on diagnosis and management.
    Am J Hematol. 2023 Aug 21. doi: 10.1002/ajh.27058.
    >> Share

  25. HRISTOV AC, Tejasvi T, Wilcox RA
    Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2023;98:1326-1332.
    >> Share

    July 2023
  26. BRADY MT, Laniewski N, Strawderman M, Chu CC, et al
    Long-term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial Bruton tyrosine kinase inhibitors therapy for chronic lymphocytic leukemia or lymphoplasmacytic lymphoma.
    Am J Hematol. 2023 Jul 23. doi: 10.1002/ajh.27038.
    >> Share

  27. LOSCOCCO GG, Ascani S, Mannelli F, Zanelli M, et al
    Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement.
    Am J Hematol. 2023 Jul 12. doi: 10.1002/ajh.27026.
    >> Share

    June 2023
  28. FENU EM, Margolskee E, Pillai V
    Transdifferentiation of B-lymphoblastic leukemia to histiocytic sarcoma after immunotherapy.
    Am J Hematol. 2023 Jun 1. doi: 10.1002/ajh.26983.
    >> Share

    May 2023
  29. BENNETT R, Ruskova A, Coomarasamy C, Theakston E, et al
    Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
    Am J Hematol. 2023 May 10. doi: 10.1002/ajh.26953.
    >> Share

  30. HUNTINGTON SF, Schuster SJ, Ding W, Koehler AB, et al
    DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
    Am J Hematol. 2023;98:739-749.
    >> Share

    April 2023
  31. MICHOT JM, Quivoron C, Sarkozy C, Danu A, et al
    Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
    Am J Hematol. 2023;98:645-657.
    >> Share

    March 2023
  32. SUN P, Li Y, Li C, Ren K, et al
    A Phase II Study of Sintilimab, Anlotinib, and Pegaspargase Sandwiched with Radiotherapy as First-line Therapy in Patients with Newly Diagnosed, Stage I-II Extranodal Natural-killer/T-cell Lymphoma.
    Am J Hematol. 2023 Mar 27. doi: 10.1002/ajh.26922.
    >> Share

  33. DAVID KA, Sundaram S, Kim SH, Vaca R, et al
    Older Patients with Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 US Cancer Centers.
    Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26919.
    >> Share

  34. GONZALEZ BARCA E, Tomas-Roca L, Esteve A, Rodriguez M, et al
    Extranodal natural killer/T-cell lymphoma nasal type in a western population: molecular profiling identifies new therapeutic targets.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26904.
    >> Share

  35. DESIKAN SP, Senapati J, Jabbour E, Abuasab T, et al
    Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
    Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26907.
    >> Share

    February 2023
  36. MEJIA SALDARRIAGA M, Alhomoud M, Roboz G, Allan JN, et al
    Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia.
    Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26878.
    >> Share

  37. ALHOMOUD M, Soave R, Kluk MJ, Shore T, et al
    Acute Hemolytic Anemia After Hematopoietic Stem Cell Transplantation: An Unusual Invader.
    Am J Hematol. 2023 Feb 6. doi: 10.1002/ajh.26873.
    >> Share

  38. CASTILLO JJ, Buske C, Trotman J, Sarosiek S, et al
    Bruton tyrosine kinase inhibitors in the management of Waldenstrom macroglobulinemia.
    Am J Hematol. 2023;98:338-347.
    >> Share

  39. AGRAWAL V, Salhotra A, Song J, Gu Z, et al
    The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse.
    Am J Hematol. 2023;98:E38-E40.
    >> Share

    January 2023
  40. ALDOSS I, Shah BD, Park JH, Muffly L, et al
    Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2023 Jan 24. doi: 10.1002/ajh.26853.
    >> Share

  41. XU W, Zhou K, Wang T, Yang S, et al
    Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
    Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26826.
    >> Share

  42. DESAI SH, Spinner MA, David K, Bachanova V, et al
    Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Am J Hematol. 2023 Jan 11. doi: 10.1002/ajh.26827.
    >> Share

  43. LASATER EA, Amin DN, Bannerji R, Mali RS, et al
    Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib study.
    Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26809.
    >> Share

  44. HRISTOV AC, Tejasvi T, Wilcox RA
    Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2023;98:193-209.
    >> Share

  45. BEATON B, Sasson SC, Rankin K, Raedemaeker J, et al
    Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses.
    Am J Hematol. 2023;98:131-139.
    >> Share

  46. HESS BT, Giri A, Park Y, Patel KK, et al
    Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26784.
    >> Share

  47. LUDVIGSEN AL-MASHHADI A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, et al
    Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26803.
    >> Share

    December 2022
  48. INAMOTO Y, Takeda W, Hirakawa T, Sakaguchi H, et al
    Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis.
    Am J Hematol. 2022;97:1568-1579.
    >> Share

    November 2022
  49. PERRIELLO VM, Falini L, Ruggeri L, Innocente A, et al
    CAR T cell-driven cerebrospinal fluid cytokine storm with confounding neurological picture in chemorefractory primary cardiac lymphoma.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26777.
    >> Share

  50. WOYACH JA
    Management of relapsed/refractory Chronic Lymphocytic Leukemia.
    Am J Hematol. 2022;97 Suppl 2:S11-S18.
    >> Share

  51. ANSELL SM
    Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2022;97:1478-1488.
    >> Share

    October 2022
  52. ALDULESCU M, Leuer K, Jennings LJ, Yap KL, et al
    Lineage switch from acute myeloid leukemia to B-lymphoblastic lymphoma with acquired PIK3R1 loss-of-function mutation.
    Am J Hematol. 2022 Oct 26. doi: 10.1002/ajh.26770.
    >> Share

  53. NOWAKOWSKI G, Maurer MJ, Cerhan JR, Dey D, et al
    Utilization of Real-World Data in Assessing Treatment Effectiveness for Diffuse Large B-Cell Lymphoma.
    Am J Hematol. 2022 Oct 17. doi: 10.1002/ajh.26767.
    >> Share

  54. KITTAI AS, Huang Y, Beckwith KA, Bhat SA, et al
    Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Am J Hematol. 2022 Oct 10. doi: 10.1002/ajh.26755.
    >> Share


  55. Abstracts from the 2022 Lymphoma, Leukemia and Myeloma Congress October 18-22, 2022.
    Am J Hematol. 2022;97 Suppl 3:S3-S40.
    >> Share

    September 2022
  56. RADKIEWICZ C, Bruchfeld JB, Weibull CE, Jeppesen ML, et al
    Sex differences in lymphoma incidence and mortality by subtype: a population-based study.
    Am J Hematol. 2022 Sep 30. doi: 10.1002/ajh.26744.
    >> Share

  57. JACOBSEN E
    Follicular lymphoma: 2023 update on diagnosis and management.
    Am J Hematol. 2022 Sep 17. doi: 10.1002/ajh.26737.
    >> Share

  58. LACKRAJ T, Barouch SB, Medeiros JJF, Pedersen S, et al
    Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma.
    Am J Hematol. 2022 Sep 10. doi: 10.1002/ajh.26726.
    >> Share

  59. ALABDALJABAR MS, Durani U, Thompson CA, Constine LS, et al
    The Forgotten Survivor: A comprehensive review on Non-Hodgkin Lymphoma Survivorship.
    Am J Hematol. 2022 Sep 7. doi: 10.1002/ajh.26719.
    >> Share

  60. ALDERUCCIO JP, Reis IM, Habermann TM, Link BK, et al
    Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.
    Am J Hematol. 2022 Sep 3. doi: 10.1002/ajh.26715.
    >> Share

  61. YING Z, Zou D, Yang H, Wu J, et al
    Preliminary Efficacy and Safety of Relmacabtagene Autoleucel (Carteyva) in Adults with Relapsed/Refractory Follicular Lymphoma in China: A Phase I/II Clinical Trial.
    Am J Hematol. 2022 Sep 1. doi: 10.1002/ajh.26711.
    >> Share

    August 2022
  62. ALDERUCCIO JP, Habermann T, Kuker R, Moskowitz CH, et al
    A roadmap for clinical trial design in marginal zone lymphoma.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26706.
    >> Share

    July 2022
  63. DU J, Wei R, Jiang S, Jiang H, et al
    CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
    Am J Hematol. 2022;97:933-941.
    >> Share

  64. ABUSHUKAIR H, Syaj S, Ababneh O, Qarqash A, et al
    First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstrom's Macroglobulinemia: A systematic review and meta-analysis.
    Am J Hematol. 2022;97:942-950.
    >> Share

    June 2022
  65. LIM JQ, Huang D, Chan JY, Laurensia Y, et al
    A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort.
    Am J Hematol. 2022 Jun 20. doi: 10.1002/ajh.26636.
    >> Share

  66. SEEGOBIN K, Li Z, Alhaj Moustafa M, Majeed U, et al
    Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003-2018).
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26635.
    >> Share

  67. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
    Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
    >> Share

    May 2022
  68. SAUL EE, Alderuccio JP, Reis IM, Zhao W, et al
    Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26591.
    >> Share

  69. EVANS MG, Crymes A, Crombie JL, Basu SS, et al
    Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID-19 recovery.
    Am J Hematol. 2022;97:666-667.
    >> Share

  70. WANG J, Zhang X, Zhou Z, Liu Y, et al
    A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
    >> Share

    April 2022
  71. MALPICA L, Marques-Piubelli ML, Beltran BE, Chavez JC, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26579.
    >> Share

  72. HOPKINS D, Smyth D, Leach M, Bain BJ, et al
    Breast implant-associated anaplastic large cell lymphoma.
    Am J Hematol. 2022 Apr 20. doi: 10.1002/ajh.26574.
    >> Share

  73. BANSAL R, Novo M, Al Saleh AS, Guerrico AG, et al
    Peak Absolute Lymphocyte Count After CAR-T Infusion Predicts Clinical Response in Aggressive Lymphoma.
    Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26561.
    >> Share

    March 2022
  74. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
    Hyposplenism in adult T-cell leukemia/lymphoma.
    Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.
    >> Share

  75. OVLISEN AK, Jakobsen LH, Kragholm KH, Nielsen RE, et al
    Mental Health Among Patients with non-Hodgkin Lymphoma: a Danish Nationwide Study of Psychotropic Drug Use in 8,750Patients and 43,750 Matched Comparators.
    Am J Hematol. 2022 Mar 17. doi: 10.1002/ajh.26538.
    >> Share

  76. EVENS AM, Brandt JS, Peer CJ, Yin T, et al
    Checkpoint Inhibitor Immunotherapy during Pregnancy for Relapsed/Refractory Hodgkin Lymphoma.
    Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26527.
    >> Share

  77. JAIN P, Wang M
    Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26523.
    >> Share

  78. TA R, Hasserjian RP, Nardi V
    An Unusual Lymphoma Involving the GI Tract and Bone Marrow.
    Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26513.
    >> Share

    February 2022
  79. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
    Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
    >> Share

  80. YHIM HY, Eshet Y, Metser U, Lajkosz K, et al
    Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pre-transplant Deauville score and residual metabolic tumor volume.
    Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26500.
    >> Share

  81. WANG Y, Zhang M, Song W, Cai Q, et al
    Chidamide plus Prednisone, Etoposide, and Thalidomide for Untreated Angioimmunoblastic T-cell Lymphoma in a Chinese Population: A Multicenter Phase II Trial.
    Am J Hematol. 2022 Feb 15. doi: 10.1002/ajh.26499.
    >> Share

  82. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
    Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Am J Hematol. 2022;97:E67-E69.
    >> Share

    January 2022
  83. DORFMAN DM, Pinkus GS
    A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
    Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.
    >> Share

  84. PHILLIPS T, Brunvand M, Chen AI, Essell J, et al
    Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
    Am J Hematol. 2022;97:E24-E27.
    >> Share

    December 2021
  85. MOSHREF RAZAVI H, Henrie R, Hrynchak M, Minor A, et al
    Aggressive B cell lymphoma with t(3;8)(q27;q24). in an elderly patient.
    Am J Hematol. 2021 Dec 6. doi: 10.1002/ajh.26430.
    >> Share

    October 2021
  86. KOZAK M, Eno C, Vail E, Kitahara S, et al
    The elusive but classic presentation of small cell variant of ALK+ anaplastic large cell lymphoma (ALCL).
    Am J Hematol. 2021 Oct 29. doi: 10.1002/ajh.26394.
    >> Share

  87. ZHANG T, Lu Y, Liu X, Zhao M, et al
    Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B cell lymphoma.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26392.
    >> Share

  88. HO M, Zanwar S, Duggan P, Carr R, et al
    Hiding in (Not So) Plain Sight: Spontaneous Tumor Lysis Syndrome due to Intravascular Large B Cell Lymphoma.
    Am J Hematol. 2021 Oct 22. doi: 10.1002/ajh.26383.
    >> Share

  89. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    >> Share

  90. BARRETO JN, Bansal R, Hathcock MA, Doleski CJ, et al
    The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy.
    Am J Hematol. 2021;96:E399-E402.
    >> Share

  91. TINTLE S, Fuda F, Chen W
    Restricted TRBC1 expression: A clonality marker for circulating Sezary cells.
    Am J Hematol. 2021;96:1338-1339.
    >> Share

  92. WESTIN JR, Kersten MJ, Salles G, Abramson JS, et al
    Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Am J Hematol. 2021;96:1295-1312.
    >> Share

  93. HRISTOV AC, Tejasvi T, A Wilcox R
    Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2021;96:1313-1328.
    >> Share


  94. Abstracts from the 2021 Lymphoma and Myeloma Congress October 19-23, 2021.
    Am J Hematol. 2021;96 Suppl 1:S3-S33.
    >> Share

    September 2021
  95. S MEHTA R, Torres Cabala CA, DiNardo CD, Daver N, et al
    Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis.
    Am J Hematol. 2021;96:E350-E353.
    >> Share

    August 2021
  96. SIOW W, Matthey F, Bain BJ
    Eosinophil morphology in the reactive eosinophilia of Hodgkin lymphoma.
    Am J Hematol. 2021 Aug 30. doi: 10.1002/ajh.26337.
    >> Share

  97. ZHANG Y, Ma S, Cai J, Yang Y, et al
    Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: a multicenter study.
    Am J Hematol. 2021 Aug 27. doi: 10.1002/ajh.26335.
    >> Share

  98. WUDHIKARN K, Bansal R, Khurana A, Hathcock MA, et al
    Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.
    Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26330.
    >> Share

  99. JURGENS EM, Ketas TJ, Zhao Z, Satlin MJ, et al
    Serologic response to mRNA COVID-19 vaccination in lymphoma patients.
    Am J Hematol. 2021 Aug 14. doi: 10.1002/ajh.26322.
    >> Share

  100. ZAIN JM, Hanona P
    Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:1027-1046.
    >> Share

    July 2021
  101. KARMALI R, Switchenko JM, Goyal S, Shanmugasundaram K, et al
    Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.
    Am J Hematol. 2021 Jul 29. doi: 10.1002/ajh.26306.
    >> Share

  102. KHURANA A, Hathcock M, Habermann TM, Al Saleh A, et al
    Lines of Therapy before Autologous Stem Cell Transplant and CAR-T Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26293.
    >> Share

  103. CASTILLO JJ, Lamacchia J, Silver J, Flynn CA, et al
    Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26291.
    >> Share

  104. MEHTA-SHAH N, Lunning MA, Moskowitz AJ, Boruchov AM, et al
    Romidepsin and lenalidomide based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts.
    Am J Hematol. 2021 Jul 12. doi: 10.1002/ajh.26288.
    >> Share

  105. VAUGHN JL, Spies D, Xavier AC, Epperla N, et al
    Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States.
    Am J Hematol. 2021;96:816-822.
    >> Share

    June 2021
  106. SARKOZY C, Michot JM, Quivoron C, Camara-Clayette V, et al
    Innovative therapies based on molecular orientation in patients with Relapse and Refractory diffuse large B cell lymphoma, results of LNH-EP1 study.
    Am J Hematol. 2021 Jun 24. doi: 10.1002/ajh.26280.
    >> Share

  107. DEFRANCESCO I, Visentini M, Zibellini S, Minafo YA, et al
    Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
    Am J Hematol. 2021;96:E210-E214.
    >> Share

    May 2021
  108. MARTINEZ-CALLE N, Wilson MR, Eyre TA, Cwynarski K, et al
    Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in Diffuse Large B-cell Lymphoma; caution required.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26257.
    >> Share

  109. PUCKRIN R, Stewart DA
    Prophylactic high-dose methotrexate in diffuse large B cell lymphoma, authors' response.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26256.
    >> Share

  110. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    >> Share

  111. KHURANA A, Dalland J, Young JR, Inwards DJ, et al
    Brexucabtagene Autoleucel Therapy Induces Complete Remission in a Primary Refractory Blastoid Mantle Cell Lymphoma with Neurolymphomatosis.
    Am J Hematol. 2021 May 13. doi: 10.1002/ajh.26233.
    >> Share

  112. BODDICKER NJ, Larson MC, Castellino A, Herrmann J, et al
    Anthracycline Treatment, Cardiovascular Risk Factors and the Cumulative Incidence of Cardiovascular Disease in a Cohort of Newly Diagnosed Lymphoma Patients from the Modern Treatment Era.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26230.
    >> Share

    April 2021
  113. DULERY R, Lamure S, Delord M, Di Blasi R, et al
    Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.
    Am J Hematol. 2021 Apr 28. doi: 10.1002/ajh.26209.
    >> Share

  114. WALTER LP, Couronne L, Jais JP, Nguyen PD, et al
    Outcome after Haematopoietic Stem Cell Transplantation in Patients with Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: a French Study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26200.
    >> Share

  115. LAM M, Touitou V, Choquet S, Cassoux N, et al
    Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26199.
    >> Share

  116. PUCKRIN R, El Darsa H, Ghosh S, Peters A, et al
    Ineffectiveness of High-Dose Methotrexate for Prevention of CNS Relapse in Diffuse Large B Cell Lymphoma.
    Am J Hematol. 2021 Apr 3. doi: 10.1002/ajh.26181.
    >> Share

  117. NAGLE SJ, Murphree C, Raess PW, Schachter L, et al
    Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
    Am J Hematol. 2021;96:455-461.
    >> Share

    April 2020
  118. WANG W, Zhang Y, Zhang L, Yang C, et al
    Intravenous methotrexate at a dose of 1 g/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study.
    Am J Hematol. 2020;95:E80-E83.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016